# Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

> **NCT01140373** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 13 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** engineered autologous T cells
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT01140373
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2010-06
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01140373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01140373, "Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01140373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*